



# Health Equity, Patient Engagement, and DEI efforts at Lupus Research Alliance

## About Lupus Research Alliance

• The Lupus Research Alliance is the largest nongovernmental, non-profit funder of lupus research worldwide. The organization aims to transform treatment by funding the most innovative lupus research, fostering diverse scientific talent, and driving discovery toward better diagnostics, improved treatments and ultimately, cure for lupus.

• Lupus Therapeutics: As the clinical research accelerator arm of Lupus Research Alliance, we partner with biopharmaceutical companies, clinical investigators, and community organizations to improve the clinical research process. Our efforts have one ultimate goal – ensuring the lupus community has more therapies that better address the unique ways lupus can affect individuals.



## Hope Inspired by Progress



### **About Lupus**


- Lupus is a complex, potentially lifethreatening autoimmune disorder that disproportionately impacts women and communities of color.
- Lupus can affect the joints, skin, brain, lungs, kidneys, and blood vessels, causing widespread inflammation and tissue damage in the affected organ.
- A heterogenous disease, lupus affects each person differently and its effects can change over time, making it one of the most difficult diseases to diagnose and treat.
- Black, Hispanic, Asian, and Native American populations are two to three times more likely to be diagnosed with lupus than white populations.





## **Prioritizing Health Equity and DEI at LRA:**





- Bolstering
   Internal DEI
   Efforts
- New Strategic
   Plan Centers
   Equity &
   Engagement



## Patient Engagement at LRA/LT

#### PALS (Patient Advocates for Lupus Studies)

- Early educational intervention delivered by peers to improve clinical trial participation
- Pilot (Phase I) concluded Fall 2021

#### Patient Advisory Boards


- Bring the patient voice as a partner to the drug development table and prioritizes the patient needs and preference
- Gain insight into disease burden while examining clinical research barriers and motivators

#### Patient Protocol Review Council

- Incorporates patient voice early in protocol development and review process
- Helps to design protocols that are less burdensome and more meaningful for patients







# Composite Score Intervention group scored higher than control at posttest on all outcomes Knowledge Attitudes Self-efficacy Intentions

Statistically significant increase



## Model for Successful Patient Engagement: Patient Advocates for Lupus Studies

- 9 out of 11 trained PALS identified as women of color.
- 68% of PALS participants identified as Black/African American, while 13% identified as Hispanic.
- Individuals who completed the PALS program demonstrated significant increases in knowledge about, attitude towards, and intention to participate in lupus clinical trials following completion of the PALS program.
- Treatment participants also demonstrated increases in **self-efficacy** three months after finishing the program.
- Additionally, participants expressed high satisfaction with the program overall.







## **Lupus Nexus & Landmark Study**



- Lupus Nexus is first-of-its-kind lupus registry, biorepository, and data exchange platform that aims to accelerate lupus research and translation.
- Created with lupus patient advisory council
- Biorepository and platform allow interactive a platform where individuals living with lupus, researchers, healthcare providers, and advocates can connect, share insights, and collaborate




## LuCIN Health Equity Working Group

- The LuCIN Community Health Equity
  Working Group brings together investigators
  and team members from across the LuCIN
  Network to identify strategies, efforts, and
  resources needed to enable the network to
  increase health equity and improve diverse
  representation in lupus clinical trials.
- As the premier lupus clinical trials network in North America, the LuCIN Network is uniquely positioned to have profound impact on the access, inclusion, and outcomes for those historically underrepresented in lupus clinical trials.



## **Lupus Research** Alliance Unites the U.S. Food & Drug **Administration (FDA) & Lupus Community to Launch Novel Public-Private Partnership**



#### Goals of Lupus Accelerating Breakthroughs Consortium

#### **Accelerate Therapies**

Bring together federal agencies, industry, academic clinical researchers, medical societies, patient advocacy groups, and people with lupus to address the most pressing obstacles to drug development and implement an action plan that has the greatest, most immediate impact on advancing lupus treatments.

#### Expand Scientific Collaboration

Facilitate an open, collaborative, and community-wide approach that connects the best and brightest minds in lupus research, helping partners share knowledge, conduct key research projects, and catalyze patient-focused lupus drug development.




#### Elevate the Voices of People with Lupus

Unite people across the lupus and research communities to ensure that the experiences, perspectives, needs, and priorities of people with lupus are meaningfully incorporated into the development of new lupus treatments.

## **Lupus Voices Council**



## **Lupus Therapeutics Healthcare Provider Directory**™






- First-of-its-kind in lupus
- Launched 08Nov2023 ~300 providers to date
- Core: LuCIN center providers
- Community practices surrounding LuCIN centers
- Support for clinical care and access to clinical trials

## **Project CHANGE**

Community-based Health Action Network to
Generate trial participation and Eliminate
disparities is a community driven approach to
increase lupus clinical trial representation among
Black and African American individuals





**Evaluation &** 

Sustainability


Participatory evaluation approach
 Identifying framework and elements to

· Planning for sustainability beyond

extrapolate and scale

duration of pilot

## **Background for Project CHANGE Framework**



- Black, Hispanic, Asian, and Native American populations are two to three times more likely to be diagnosed with lupus than white populations and often have greater severity of disease.
- Black individuals make up 43% of lupus cases but account for just 14% of clinical trial participants.
- Evidence suggests that observed disparities in health outcomes in lupus are largely due to differences in opportunities to achieve optimal health.

- Sheikh SZ, Wanty NI, Stephens J, Holtz KD, McCalla S. The State of Lupus Clinical Trials: Minority Participation Needed. J Clin Med. 2019 Aug 17;8(8):1245. doi: 10.3390/jcm8081245. PMID: 31426523; PMCID: PMC6722692.
- Ioannis Parodis, Cristina Lanata, Dionysis Nikolopoulos, Ashira Blazer, Jinoos Yazdany, Reframing health disparities in SLE: A critical reassessment of racial and ethnic differences in lupus disease outcomes, Best Practice & Research Clinical Rheumatology, 2023, 101894, ISSN 1521-6942, https://doi.org/10.1016/j.berh.2023.101894.

### **Project CHANGE Team**

#### Project CHANGE Steering Committee

#### Edith Williams, PhD Steering Committee Co-Chair Medical University of South Carolina wiled@musc.edu Dexter Cooper, MPH



KDH Research & Communication dcooper@kdhrc.com



hjohnson@lupuscsc.org



#### Salathiel Deloach Steering Committee Co-Chair



DeLoach Lupus Foundation of Savannah, GA deloach03@hotmail.com

Carla Boutin-Foster, MD



SUNY Downstate Health Sciences University carla.boutin-foster@downstate.edu

Jessica Williams, MD





cgoodman@balmingilead.org

Emory University School of Medicine jessica.williams2@emory.edu

Chris Reed, JD

Christopher.reed@live.com



tantony@ideo.com

#### Lupus Therapeutics Team



Claire Finney, MPH Associate Director. Health Equity

Taylor Adjei, MPH Senior Program Coordinator, Health President, Lupus Equity

Stacie Bell, PhD **Executive Vice** Therapeutics

#### Research & Evaluation Partners



Decision Information Resources, Inc.

- Sylvia Epps, PhD
- Tiara Jackson, PhD
- Cynthia Castaldo-Walsh, PhD
- Ventrice Shillingford-Cole, MPH
- Oriana Perez, MPH
- Jill Helmick

#### **LuCIN Centers**







MEDICAL CENTER



- Nikki Wanty, MA
- Dexter Cooper, MPH

## Coming Up: LRA Walk to Cure Lupus and more



## **Contact Us and Learn More**



Claire Finney, MPH

Associate Director, Health Equity

cfinney@lupusresearch.org





Taylor Adjei, MPH
Senior Program Coordinator, Health Equity

• tadjei@lupusresearch.org

